Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma
Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, 1:1, double blinded phase II trial. Patients with
unresectable malignant pleural mesothelioma (MPM) will be randomized between arm A:
nintedanib and arm B:placebo
Phase:
Phase 2
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC